+

WO2008127659A3 - Traitements combinés contre le cancer - Google Patents

Traitements combinés contre le cancer Download PDF

Info

Publication number
WO2008127659A3
WO2008127659A3 PCT/US2008/004719 US2008004719W WO2008127659A3 WO 2008127659 A3 WO2008127659 A3 WO 2008127659A3 US 2008004719 W US2008004719 W US 2008004719W WO 2008127659 A3 WO2008127659 A3 WO 2008127659A3
Authority
WO
WIPO (PCT)
Prior art keywords
tyrosine kinase
kinase inhibitor
inhibitor
wild type
romidepsin
Prior art date
Application number
PCT/US2008/004719
Other languages
English (en)
Other versions
WO2008127659A2 (fr
Inventor
Eugene P. Frenkel
Original Assignee
The Board Of Regents Of The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Regents Of The University Of Texas System filed Critical The Board Of Regents Of The University Of Texas System
Publication of WO2008127659A2 publication Critical patent/WO2008127659A2/fr
Publication of WO2008127659A3 publication Critical patent/WO2008127659A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions et des procédés permettant le traitement de troubles à prolifération cellulaire en utilisant au moins un inhibiteur de la DAC et au moins un inhibiteur de la tyrosine kinase. En particulier, l'invention concerne un traitement combiné permettant de traiter un trouble prolifératif (par exemple, le cancer) comprenant de la romidepsine et un inhibiteur de la tyrosine kinase. Lorsqu'ils sont administrés ensemble, la romidepsine et l'inhibiteur de la tyrosine kinase (par exemple, l'erlotinib) interagissent pour induire l'apoptose. L'effet est particulièrement marqué dans les cancers du poumon non à petites cellules (CPNPC) de type sauvage, particulièrement les cellules de cancer non à petites cellules EGFR de type sauvage et KRAS de type sauvage. La présente invention propose des procédés permettant de détruire les cellules malignes in vitro et in vivo. Des compositions pharmaceutiques, des préparations, et des trousses contenant la romidepsine et un inhibiteur de la tyrosine kinase sont également proposés.
PCT/US2008/004719 2007-04-13 2008-04-11 Traitements combinés contre le cancer WO2008127659A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92324907P 2007-04-13 2007-04-13
US60/923,249 2007-04-13

Publications (2)

Publication Number Publication Date
WO2008127659A2 WO2008127659A2 (fr) 2008-10-23
WO2008127659A3 true WO2008127659A3 (fr) 2009-11-05

Family

ID=39722554

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/004719 WO2008127659A2 (fr) 2007-04-13 2008-04-11 Traitements combinés contre le cancer

Country Status (1)

Country Link
WO (1) WO2008127659A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009006969A (es) 2006-12-29 2010-04-07 Gloucester Pharmaceuticals Purificacion de romidepsina.
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
AU2013201937B8 (en) * 2012-01-12 2015-08-20 Celgene Corporation Romidepsin formulations and uses thereof
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
EP2968565A2 (fr) * 2013-03-14 2016-01-20 Genentech, Inc. Méthodes de traitement du cancer et de prévention d'une résistance à un médicament anticancéreux
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
WO2017164887A1 (fr) * 2016-03-25 2017-09-28 OSI Pharmaceuticals, LLC Régime de dosage pulsé et procédés de traitement
US10583142B2 (en) 2016-03-25 2020-03-10 OSI Pharmaceuticals, LLC Pulse dosing regimen and methods of treatment
GB2584441A (en) * 2019-06-03 2020-12-09 Fenomark Diagnostics Ab Medical uses, methods and uses

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004043390A (ja) * 2002-07-12 2004-02-12 Nagoya Industrial Science Research Inst 抗腫瘍剤
WO2004024160A1 (fr) * 2002-09-13 2004-03-25 Virginia Commonwealth University Combinaison de a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine et b) d'un inhibiteur de l'histone deacetylase pour le traitement de la leucemie
EP1574213A1 (fr) * 2004-03-11 2005-09-14 Yih-Lin Chung Usage d'inhibiteurs de la histone deacetylase pour augmenter l'action therapeutique dans la radiotherapie et la chemotherapie
WO2006099396A2 (fr) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Inhibiteurs d'histone deacetylase permettant de sensibiliser des cellules cancereuses aux inhibiteurs du facteur de croissance epidermique
WO2007039403A1 (fr) * 2005-09-21 2007-04-12 Nycomed Gmbh Utilisation de sels de chlorhydrate de sulfonylpyrrole comme inhibiteurs de l'histone deacetylase
WO2007100385A2 (fr) * 2005-10-31 2007-09-07 Genentech, Inc. Conjugués anticorps-médicaments à base de depsipeptide macrocyclique et méthodes associées

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004043390A (ja) * 2002-07-12 2004-02-12 Nagoya Industrial Science Research Inst 抗腫瘍剤
WO2004024160A1 (fr) * 2002-09-13 2004-03-25 Virginia Commonwealth University Combinaison de a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine et b) d'un inhibiteur de l'histone deacetylase pour le traitement de la leucemie
EP1574213A1 (fr) * 2004-03-11 2005-09-14 Yih-Lin Chung Usage d'inhibiteurs de la histone deacetylase pour augmenter l'action therapeutique dans la radiotherapie et la chemotherapie
WO2006099396A2 (fr) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Inhibiteurs d'histone deacetylase permettant de sensibiliser des cellules cancereuses aux inhibiteurs du facteur de croissance epidermique
WO2007039403A1 (fr) * 2005-09-21 2007-04-12 Nycomed Gmbh Utilisation de sels de chlorhydrate de sulfonylpyrrole comme inhibiteurs de l'histone deacetylase
WO2007100385A2 (fr) * 2005-10-31 2007-09-07 Genentech, Inc. Conjugués anticorps-médicaments à base de depsipeptide macrocyclique et méthodes associées

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BATES DAVID: "ZD-6474. AstraZeneca", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, vol. 4, no. 12, 1 December 2003 (2003-12-01), pages 1468 - 1472, XP009050316, ISSN: 1472-4472 *
BATES S E ET AL: "Histone deacetylase inhibitors in combinations: Will the preclinical promises be kept?", CANCER JOURNAL 2007 LIPPINCOTT WILLIAMS AND WILKINS USA, vol. 13, no. 2, March 2007 (2007-03-01), pages 80 - 83, XP008111378, ISSN: 1528-9117 1540-336X *
DANCEY JANET E: "Recent advances of molecular targeted agents: opportunities for imaging.", CANCER BIOLOGY & THERAPY 2003 NOV-DEC, vol. 2, no. 6, November 2003 (2003-11-01), pages 601 - 609, XP008111441, ISSN: 1538-4047 *
DATABASE TXTJPT EUROPEAN PATENT OFFICE, THE HAGUE, NL; XP002545391 *
HIROKAWA ET AL: "Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors)", CANCER LETTERS, NEW YORK, NY, US, vol. 245, no. 1-2, 22 December 2006 (2006-12-22), pages 242 - 251, XP005813564, ISSN: 0304-3835 *
KAWANO T ET AL: "Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect", ANTICANCER RESEARCH 200409 GR, vol. 24, no. 5 A, September 2004 (2004-09-01), pages 2705 - 2712, XP008111371, ISSN: 0250-7005 *
MEHNERT J M ET AL: "Histone deacetylase inhibitors: Biology and mechanism of action", CANCER JOURNAL 2007 LIPPINCOTT WILLIAMS AND WILKINS USA, vol. 13, no. 1, January 2007 (2007-01-01), pages 23 - 29, XP008111426, ISSN: 1528-9117 1540-336X *
MORADEI O ET AL: "HISTONE DEACETYLASE INHIBITORS: LATEST DEVELOPMENTS, TRENDS AND PROSPECTS", CURRENT MEDICINAL CHEMISTRY. ANTI-CANCER AGENTS, BENTHAM SCIENCE PUBLISHERS, HILVERSUM, NL, vol. 5, no. 5, 1 January 2005 (2005-01-01), pages 529 - 560, XP009065870, ISSN: 1568-0118 *
NGUYEN D M ET AL: "Growth factor receptors as targets for lung cancer therapy", SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY 200403 US, vol. 16, no. 1, March 2004 (2004-03-01), pages 3 - 12, XP008111355, ISSN: 1043-0679 *
ROSATO R R ET AL: "Histone deacetylase inhibitors in clinical development", EXPERT OPINION ON INVESTIGATIONAL DRUGS 200401 GB, vol. 13, no. 1, January 2004 (2004-01-01), pages 21 - 38, XP002543980, ISSN: 1354-3784 *
SMITH P W ET AL: "Novel Targeted Therapies for Non-Small Cell Lung Cancer", THORACIC SURGERY CLINICS - THE BIOLOGY OF THORACIC SURGERY: INNOVATION IN STAGING AND TREATMENT 200611 US, vol. 16, no. 4, November 2006 (2006-11-01), pages 353 - 366, XP008111362, ISSN: 1547-4127 *
TAUCHI T ET AL: "Molecular mechanisms of resistance of leukemia to imatinib mesylate", LEUKEMIA RESEARCH 200405 GB, vol. 28, no. SUPPL. 1, May 2004 (2004-05-01), pages S39 - S45, XP005157790, ISSN: 0145-2126 *
YASUHIKO KANO ET AL: "Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines", INVESTIGATIONAL NEW DRUGS ; THE JOURNAL OF NEW ANTICANCER AGENTS, KLUWER ACADEMIC PUBLISHERS, BO, vol. 25, no. 1, 22 July 2006 (2006-07-22), pages 31 - 40, XP019434183, ISSN: 1573-0646 *
YASUI H ET AL: "Recent advances in the treatment of Multiple Myeloma", CURRENT PHARMACEUTICAL BIOTECHNOLOGY 200610 NL, vol. 7, no. 5, October 2006 (2006-10-01), pages 381 - 393, XP008111424, ISSN: 1389-2010 *
ZHANG WEI ET AL: "Histone deacetylase inhibitor FK228 enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 48, April 2007 (2007-04-01), & 98TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; LOS ANGELES, CA, USA; APRIL 14 -18, 2007, pages 591, XP008111359, ISSN: 0197-016X *

Also Published As

Publication number Publication date
WO2008127659A2 (fr) 2008-10-23

Similar Documents

Publication Publication Date Title
WO2008127659A3 (fr) Traitements combinés contre le cancer
Kim et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin
Zhang et al. Quercetin enhances cisplatin sensitivity of human osteosarcoma cells by modulating microRNA-217-KRAS axis
WO2008091701A3 (fr) Utilisation d'anticorps anti-egfr dans le traitement de maladie médiée par des mutants de récepteur du facteur de croissance épidermique (egfr)
Hu et al. Methionine depletion with recombinant methioninase: in vitro and in vivo efficacy against neuroblastoma and its synergism with chemotherapeutic drugs
MX2010006739A (es) Compuestos pirido[2,3-b]pirazina-8-sustituidos y su uso.
WO2008144507A3 (fr) Inhibiteurs de spirooxindole de kinase de l'aurore
WO2006028655A3 (fr) Genes, compositions, kits, et methodes pour identification, evaluation, prevention et therapie du cancer de la prostate
PL1951729T3 (pl) Pochodne pirymidyny połączone przez atom tlenu
WO2003009814A3 (fr) Nouveaux genes, compositions, trousses et methodes d'identification, evaluation, prevention, et traitement du cancer de la prostate
NO20090623L (no) Forbindelser for behandling av proliferative lidelser
WO2005097137A3 (fr) Inhibiteurs de proteines kinases ameliores a base de quinazoline
WO2012135592A3 (fr) Agents d'imagerie théranostique et leurs procédés d'utilisation
WO2003097835A3 (fr) Compositions et procedes destines au traitement du cancer
Schrauwen et al. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
NZ592326A (en) Erbb-3 (her3)-selective combination therapy
PH12022551371A1 (en) Macrocycles for use in treating disease
Longton et al. Appropriate sequence for afatinib and cisplatin combination improves anticancer activity in head and neck squamous cell carcinoma
WO2008035365A3 (fr) Inhibition médiée par l'interférence à l'arn de l'aurora-kinase b et ses combinaisons en tant thérapie anticancéreuse
Wu et al. Inhibition of PARP1 by small interfering RNA enhances docetaxel activity against human prostate cancer PC3 cells
Jain et al. Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms
Matheson et al. The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo
Karagülle et al. Synergistic effects of ozone with doxorubicin on the proliferation, apoptosis and metastatic profile of luminal-B type human breast cancer cell line
WO2007126787A3 (fr) Réactifs et procédés destinés au traitement et à la prévention du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08742791

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/010852

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08742791

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0810837

Country of ref document: BR

Free format text: APRESENTE O COMPLEMENTO DO TEXTO EM PORTUGUES, ADAPTADO A NORMA VIGENTE, DO PEDIDO CONFORME DEPOSITO INTERNACIONAL INICIAL (RELATORIO DESCRITIVO E DESENHO SE HOUVER), CONFORME DETERMINA O ATO NORMATIVO 128/97 NO ITEM 9.2.1

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0810837

Country of ref document: BR

Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL POR NAO ATENDER AS DETERMINACOES REFERENTES A ENTRADA DO PEDIDO NA FASE NACIONAL E POR NAO CUMPRIMENTO DA EXIGENCIA FORMULADA NA RPI NO 2321

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载